STING

STING agonist-13 is an agonist of the stimulator of interferon genes (STING), promoting cancer immunity through STING-mediated immune activation. This compound effectively stimulates STING downstream signaling pathways, enhancing type I interferon responses. In preclinical studies, STING agonist-13 has demonstrated a significant reduction in tumor volume and the establishment of immunological memory, suggesting potential applications in cancer immunotherapy.

STING antagonist-3 is a highly effective antagonist of the stimulator of interferon genes (STING) with an IC50 of 2.3 nM against human wild-type STING, as well as against the gain-of-function mutants N154S and V155M. This compound has been shown to inhibit the production of IFN-α2a in stimulated human whole blood and to reduce IP-10 levels in activated human dermal microvascular endothelial cells (HMVEC-d). STING antagonist-3 is valuable for research in autoimmune diseases, autoinflammatory diseases, interferonopathies, and fibrotic disorders.

diABZI-a1 is an orthosteric STING agonist that demonstrates an EC50 of 117 nM for the induction of IFNβ in human peripheral blood mononuclear cells (PBMCs). This compound is particularly relevant for research applications focused on monogenic autoinflammatory diseases, such as SAVI syndrome. Its ability to specifically activate the STING pathway makes diABZI-a1 a valuable tool for investigating immune responses and potential therapeutic interventions.

STING agonist-44 is a potent and selective agonist targeting the STING pathway. With an EC50 value of 5.68 µM for IRF induction in THP1 cells and 2.212 µM in RAW cells, this compound effectively stimulates the production of type I interferons and pro-inflammatory cytokines, such as CXCL10 and TNFα. STING agonist-44 is a valuable tool for research into cancer immunotherapy and related inflammatory conditions.

STING agonist-9 is a potent agonist of the STING (Stimulator of Interferon Genes) pathway, exhibiting an EC50 of 1.2 nM for human STING and 32.82 μM for mouse STING. This compound is known for its significant antitumor activity, making it a valuable tool for investigating immune responses in cancer research. STING agonist-9 is applicable in studies focused on immune activation and tumor microenvironment modulation.

STING modulator-5 is an inhibitor of the stimulator of interferon genes (STING) pathway, displaying a pIC50 value of 9.5. This compound effectively antagonizes peripheral blood mononuclear cells (PBMC) with a pIC50 of 8.1 and demonstrates activity against THP-1 cells. STING modulator-5 is a valuable tool for studying immunological diseases and exploring therapeutic avenues targeting STING-related signaling pathways.

STING modulator-3 is a selective STING inhibitor that targets the R232 variant of STING, exhibiting an inhibition constant (Ki) of 43.1 nM in scintillation proximity assays. This compound does not influence IRF-3 activation or TNF-β induction in THP-1 cells, making it a valuable tool for studying STING-mediated signaling pathways and their implications in immune responses and inflammatory diseases. Its specificity and potency provide researchers with a resource for exploring STING-related mechanisms in various biological contexts.

Parent CDN is a cyclic dinucleotide that acts as a Stimulator of Interferon Genes (STING) agonist. It has demonstrated significant anti-tumor activity by enhancing the innate immune response. This compound is utilized in research aimed at understanding immune modulation and cancer immunotherapy.

SAP-04 is a potent STING agonist that activates the stimulator of interferon genes pathway, enhancing innate immune responses. This compound demonstrates significant immunomodulatory effects, making it a valuable tool in cancer therapy research. Its oral bioactivity provides convenience for in vivo studies, facilitating the exploration of immune-mediated mechanisms in tumor immunology.

(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide is a potent STING (stimulator of interferon genes) agonist. It exhibits a significant inhibitory effect on 3H-cGAMP binding to STING, with an IC50 value of 14 μM. This compound is valuable for research applications in tumor biology and immune response modulation, particularly in the context of cancer immunotherapy.

Clonixeril (NSC 335504) is a non-nucleotide modulator of human STING (hSTING), exhibiting a unique dual mechanism of action. It acts as a weak agonist at micromolar concentrations while demonstrating antagonistic properties of the hSTINGWT pathway at low femtomolar and attomolar levels. Clonixeril effectively reduces hSTING oligomerization, proving useful in elucidating the complexities of STING signaling and its role in immune responses. This compound serves as a valuable tool for research in immunology and drug discovery targeting STING-related pathways.

STING agonist-29 is a small-molecule agonist targeting the stimulator of interferon genes (STING). This compound demonstrates the ability to activate the STING pathway, leading to the induction of type I interferons and pro-inflammatory cytokines. It is particularly notable for its antiviral activity against SARS-CoV strains, making it a valuable tool for research focused on innate immunity and viral infection responses.

STING Agonist-43 is a selective STING (Stimulator of Interferon Genes) agonist that activates the cGAMP-dependent STING signaling pathway, with an EC50 of 20.53 μM. This compound enhances STING oligomerization, leading to increased activation and subsequent immune response. In preclinical studies, STING agonist-43 demonstrated antitumor efficacy in a mouse melanoma model, making it a valuable tool for investigating cancer immunity and the potential for immunotherapeutic strategies.

STING agonist-34 is a potent stimulator of the STING pathway, exhibiting an IC50 value of 1.15 μM and an EC50 value of 0.38 μM in THP1 cells. This compound activates the cGAS-STING signaling pathway, promoting type I interferon production and enhancing immune responses. STING agonist-34 is applicable in cancer research and immunotherapy studies, offering potential insights into tumor microenvironments and therapeutic strategies against malignancies.

STING agonist-25 (CF505) is a non-nucleotide small-molecule activator of the Stimulator of Interferon Genes (STING). This compound enhances the phosphorylation of STING, TBK1, and IRF3, leading to elevated levels of pro-inflammatory cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-25 shows potential in antiviral research, particularly against strains of SARS-CoV.

STING agonist-10 is a potent small molecule cyclic urea that activates the Stimulator of Interferon Genes (STING) pathway, with an EC50 of 2600 nM. This compound enhances the immune response by stimulating the production of type I interferons, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity holds potential for applications in the treatment of various cancers and infectious diseases.

BSP16 is a potent agonist of stimulator of interferon genes (STING), functioning through selective activation of the STING pathway. It exhibits significant biological activity in promoting immune responses, making it a valuable tool for cancer research and immunotherapy studies. BSP16 enables researchers to explore the therapeutic potential of STING activation in various malignancies.

STING agonist-48 is a selective agonist that activates the Stimulator of Interferon Genes (STING) pathway, demonstrating an EC50 value of 4.02 μM in vitro. It preferentially binds to the transmembrane domain, influencing downstream immune responses. This compound enhances immunogenicity by promoting IgG and Th1/Th2 cytokine responses in humanized STING mice, making it a valuable tool for investigating inflammation-related diseases and potential adjuvant therapies.

STING agonist-21 is a potent STING agonist that demonstrates an EC50 of 592.8 nM. It is designed to activate the stimulator of interferon genes (STING) pathway, which plays a crucial role in immune response modulation. This compound is primarily utilized in cancer research to investigate its effects on tumor immunity and potential therapeutic applications in oncological therapies.

Ulevostinag (isomer 2) is a selective STING (Stimulator of Interferon Genes) agonist. It activates the STING pathway, leading to enhanced production of type I interferons and pro-inflammatory cytokines. This compound is primarily utilized in research focused on cancer immunotherapy, infectious diseases, and autoimmune disorders to investigate the therapeutic potential of STING activation in modulating immune responses.

STING agonist-38 is a potent agonist of the stimulator of interferon genes (STING), demonstrating an EC50 of 0.05 μM in THP1 cells. This compound exhibits notable oral bioactivity and can effectively activate STING-mediated immune responses. It is valuable for research in immuno-oncology and pathogen response studies.

STING modulator-7 is a potent modulator of the stimulator of interferon genes (STING), enhancing the signaling pathway associated with innate immune responses. This compound exhibits significant biological activity in activating STING-dependent pathways, promoting type I interferon production and immune cell activation. It is primarily utilized in research applications focused on cancer immunotherapy, infectious disease models, and studies of immune system regulation.

Ulevostinag (isomer 3) is a potent STING (Stimulator of Interferon Genes) agonist that functions through the activation of the STING pathway, leading to the induction of type I interferons and other cytokines. This compound has demonstrated significant biological activity in promoting anti-tumor immune responses, making it an essential tool for cancer immunotherapy research. Its ability to modulate immune signaling pathways positions Ulevostinag (isomer 3) as a valuable reagent in the study of immune activation and anti-cancer strategies.

Ulevostinag (isomer 4) is a potent STING (Stimulator of Interferon Genes) agonist that activates the STING signaling pathway, leading to the production of type I interferons and other pro-inflammatory cytokines. This compound enhances the immune response, making it valuable for research in cancer immunotherapy and infectious disease. Ulevostinag (isomer 4) serves as an important tool for studying STING-mediated pathways and their role in immune modulation.

diABZI-V/C-DBCO is a potent STING agonist with an EC50 of 1.47 nM. It activates the STING pathway to promote the production of type I interferons, particularly IFN-β, enhancing immune responses. This compound acts as a substrate for cathepsin B, leading to the release of active diABZI-amine through cathepsin B-mediated cleavage. In preclinical studies using an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO has been shown to elevate serum levels of IFN-β and increase the frequency of granzyme B+ CD8+ T cells, making it valuable for research in triple-negative breast cancer.

SNX281 is a selective STING agonist that functions by inducing homodimerization at the STING binding site, leading to a conformational shift that activates STING and initiates downstream signaling pathways. This compound effectively stimulates the production of type I interferons, including IFN-β, as well as TNF-α and IL-6, resulting in enhanced T cell responses and prolonged immune memory. SNX281 demonstrates anti-tumor activity and is valuable for research applications in colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer.

2'2'-cGAMP is a synthetic cyclic dinucleotide (CDN) that targets the STING (Stimulator of Interferon Genes) pathway, playing a crucial role in the immune response. It effectively induces the production of interferon-beta (IFN-β), a key cytokine involved in antiviral defense. While 2'2'-cGAMP exhibits a weaker affinity for STING compared to 2'3'-cGAMP, it demonstrates a stronger interaction than other CDNs, making it valuable for research in immunology and therapeutic applications related to immune modulation.